These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24170753)

  • 21. Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial.
    Jakubowicz D; Landau Z; Tsameret S; Wainstein J; Raz I; Ahren B; Chapnik N; Barnea M; Ganz T; Menaged M; Mor N; Bar-Dayan Y; Froy O
    Diabetes Care; 2019 Dec; 42(12):2171-2180. PubMed ID: 31548244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine.
    King AB; Clark D; Wolfe GS
    Endocr Pract; 2012; 18(4):558-62. PubMed ID: 22548951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing hypoglycemia frequency using flash glucose monitoring in older Japanese patients with type 2 diabetes receiving oral hypoglycemic agents.
    Abe H; Shikuma J; Suwanai H; Sano K; Okumura T; Kan K; Takahashi T; Miwa T; Suzuki R; Odawara M
    Geriatr Gerontol Int; 2019 Oct; 19(10):1030-1035. PubMed ID: 31486247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of blinded retrospective continuous glucose monitoring on clinical decision making and glycemic control in persons with type 2 diabetes on insulin therapy.
    Ribeiro RT; Andrade R; Nascimento do Ó D; Lopes AF; Raposo JF
    Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1267-1275. PubMed ID: 33612381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond HbA1c.
    Bloomgarden Z
    J Diabetes; 2017 Dec; 9(12):1052-1053. PubMed ID: 28792665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in HbA1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change.
    Hirst JA; Stevens RJ; Farmer AJ
    PLoS One; 2014; 9(3):e92458. PubMed ID: 24667212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes.
    Monnier L; Wojtusciszyn A; Colette C; Owens D
    Diabetes Technol Ther; 2011 Aug; 13(8):813-8. PubMed ID: 21561372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
    Mathieu C; Dandona P; Phillip M; Oron T; Lind M; Hansen L; Thorén F; Xu J; Langkilde AM;
    Diabetes Care; 2019 Jun; 42(6):1081-1087. PubMed ID: 30967434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study.
    Conget I; Castaneda J; Petrovski G; Guerci B; Racault AS; Reznik Y; Cohen O; Runzis S; de Portu S; Aronson R;
    Diabetes Technol Ther; 2016 Jan; 18(1):22-8. PubMed ID: 26241790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Association between sleep disorders and dawn phenomenon in patients with type 2 diabetes mellitus].
    Ren H; Chen L; Shan C; Yang J; Zheng M; Wang Y; Xu Y; Yang Y; Chang B
    Zhonghua Yi Xue Za Zhi; 2015 Apr; 95(16):1209-13. PubMed ID: 26081502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Self-Monitoring of Blood Glucose in Youth-Onset Type 2 Diabetes: Results From the TODAY Study.
    Weinstock RS; Braffett BH; McGuigan P; Larkin ME; Grover NB; Walders-Abramson N; Laffel LM; Chan CL; Chang N; Schwartzman BE; Barajas RA; Celona-Jacobs N; Haymond MW;
    Diabetes Care; 2019 May; 42(5):903-909. PubMed ID: 30833375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: the Fremantle Diabetes Study.
    Davis TME; Chubb SAP; Curtis BH; Barraclough H; Davis WA
    Intern Med J; 2018 Oct; 48(10):1215-1221. PubMed ID: 29230931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dawn phenomenon: its frequency in non-insulin-dependent diabetic patients on conventional therapy.
    Atiea JA; Ryder RR; Vora J; Owens DR; Luzio SD; Williams S; Hayes TM
    Diabetes Care; 1987; 10(4):461-5. PubMed ID: 3304895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-response between frequency of interruption of sedentary time and fasting glucose, the dawn phenomenon and night-time glucose in Type 2 diabetes.
    Paing AC; McMillan KA; Kirk AF; Collier A; Hewitt A; Chastin SFM
    Diabet Med; 2019 Mar; 36(3):376-382. PubMed ID: 30264906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.